Tenofovir Alafenamide prior authorization at Blue Cross Blue Shield of Michigan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Blue Cross Blue Shield of Michigan reviews Tenofovir Alafenamide prior authorizations against its medical policy . Blue Cross Blue Shield of Michigan-specific context: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Michigan's medical policy URL referenced in the cover letter
Blue Cross Blue Shield of Michigan's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy via OptumRx (PBM since 2024)
- Site-of-care reductions for infusions
- Behavioral health prior auth
- OON balance bill disputes
If the PA is denied
Blue Cross Blue Shield of Michigan gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.bcbsm.com) with the same packet plus a peer-reviewed citation supporting Tenofovir Alafenamidefor the patient's indication.
Contact Blue Cross Blue Shield of Michigan
- Provider portal: https://providers.bcbsm.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Michigan need for Tenofovir Alafenamide prior auth?
Blue Cross Blue Shield of Michigan's typical PA packet for Tenofovir Alafenamide: (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Blue Cross Blue Shield of Michigan?
Standard Tenofovir Alafenamide PA decisions at Blue Cross Blue Shield of Michigan: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Blue Cross Blue Shield of Michigan most often reject Tenofovir Alafenamide for?
Across Blue Cross Blue Shield of Michigan's book the common rejection patterns include: Step therapy via OptumRx (PBM since 2024); Site-of-care reductions for infusions; Behavioral health prior auth. For Tenofovir Alafenamide specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Michigan on Tenofovir Alafenamide?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the Tenofovir Alafenamide PA packet
Open ApprovalHelp — generate a Tenofovir Alafenamide prior-auth packet tailored to Blue Cross Blue Shield of Michigan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com